ILADS Treatment Guidelines

Expert Rev Anti Infect Ther. 2014 Sep; 12(9): 1103–1135.

Published online 2014 Jul 30. doi:  10.1586/14787210.2014.940900

PMCID: PMC4196523

 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196523/ 

Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease

Daniel J Cameron,^*,1 Lorraine B Johnson,² and Elizabeth L Maloney³

¹International Lyme and Associated Diseases Society,, PO Box 341461, Bethesda MD, 20827-1461,, USA

²LymeDisease.org,, PO Box 1352, Chico, CA 95927,, USA

³Partnership for Healing and Health Ltd,, PO Box 84, Wyoming, MN 55092,, USA

*Author for correspondence: Phone: +1 914 666 4665, ; Email: moc.dmnoremacleinad@tcatnoc

Author information ► Copyright and License information ►

 

Copyright © Informa UK, Ltd.

This is an open-access article distributed under the terms of the CC-BY-NC-ND 3.0 License which permits users to download and share the article for non-commercial purposes, so long as the article is reproduced in the whole without changes, and provided the original source is credited.

This article has been cited by other articles in PMC.

 

Go to:

Abstract

Evidence-based guidelines for the management of patients with Lyme disease were developed by the International Lyme and Associated Diseases Society (ILADS). The guidelines address three clinical questions – the usefulness of antibiotic prophylaxis for known tick bites, the effectiveness of erythema migrans treatment and the role of antibiotic retreatment in patients with persistent manifestations of Lyme disease. Healthcare providers who evaluate and manage patients with Lyme disease are the intended users of the new ILADS guidelines, which replace those issued in 2004 (Exp Rev Anti-infect Ther 2004;2:S1–13). These clinical practice guidelines are intended to assist clinicians by presenting evidence-based treatment recommendations, which follow the Grading of Recommendations Assessment, Development and Evaluation system. ILADS guidelines are not intended to be the sole source of guidance in managing Lyme disease and they should not be viewed as a substitute for clinical judgment nor used to establish treatment protocols.

Keywords: antibiotic prophylaxis, antibiotics, erythema migrans, GRADE, Lyme disease, persistent disease, treatment

download complete guideline in .pdf format from above link
_______________________________________________________

 

National Guidelines Clearinghouse

 

http://www.guideline.gov/content.aspx?id=49320 

Guideline Summary

Guideline Title Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.                                                                                              Bibliographic Source(s) Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014 Sep;12(9):1103-35. [213 references] PubMed Guideline Status This is the current release of the guideline. This guideline updates a previous version: Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther. 2004;2(1 Suppl):S1-13. [66 references] This guideline meets NGC's 2013 (revised) inclusion criteria.

download complete guideline in .pdf format from above link